Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07621653

Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\*. \*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.

Key Details

Gender

All

Age Range

6 Weeks - 55 Years

Study Type

OBSERVATIONAL

Enrollment

706

Start Date

2026-07-01

Completion Date

2027-11-23

Last Updated

2026-07-29

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Locations (9)

Investigational Site Number: 410009

Busan, South Korea

Investigational Site Number: 410011

Daegu, South Korea

Investigational Site Number: 410003

Goyang, South Korea

Investigational Site Number: 410008

Gwangju, South Korea

Investigational Site Number: 410010

Hanam, South Korea

Investigational Site Number: 410006

Iksan, South Korea

Investigational Site Number: 410005

Seongnam, South Korea

Investigational Site Number: 410004

Seoul, South Korea

Investigational Site Number: 410007

Seoul, South Korea